Brittany Cote

Articles

Expert Discusses Tissue Versus Liquid Biopsy in Next-Generation Sequencing in Lung Cancer

April 1st 2020

Lynette M. Sholl, MD, discusses the evolving use of liquid and tissue biopsies for next-generation sequencing in the treatment paradigm for patients with lung cancer.

Familial History of Prostate Cancer Strongly Linked With Early-Onset Disease

March 30th 2020

While the risk of prostate cancer varies by family history, it is strongly associated with early onset of disease.

Community Oncologist Discusses CAR T-Cell Therapy and Other Hematology Advances

March 27th 2020

Sameer Desai, MD, discusses his experience in the hematology field and how CAR T-cell therapy has evolved and its potential integration into community centers.

Prevention of Pathologic Fractures After Soft Tissue Sarcomas by the Spread of Awareness

March 25th 2020

R. Lor Randall, MD, FACS, discusses the occurrence, treatment, and prevention methods of pathologic fractures in patients with soft tissue sarcomas.

68Ga-PSMA-11 PET Imaging Poised to Be Useful Management Tool in Biochemically Recurrent Prostate Cancer

March 25th 2020

Wolfgang Fendler, MD, highlights the potential impact 68Ga-PSMA-11 PET imaging may have on the treatment of patients with biochemically recurrent prostate cancer.

Mesa Discusses Next Steps in Myelofibrosis

March 25th 2020

Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.

High-Dose Cytarabine Induction Regimens Elicit High Responses in Transplant-Eligible MCL

March 23rd 2020

Reid W. Merryman, MD, discusses the impact of adding high-dose cytarabine to bendamustine and rituximab as an induction regimen for patients with mantle cell lymphoma.

Cell-Free DNA Shows Potential in Identifying Transformed Castration-Resistant Neuroendocrine Prostate Cancer

March 20th 2020

Himisha Beltran, MD, discusses research evaluating cell-free DNA to identify therapy resistance in prostate cancer.

Expert Highlights Shifting Management of Localized Bladder Cancer

March 19th 2020

John P. Sfakianos, MD, discusses some of the optimal and evolving management strategies in localized bladder cancer.

Immunotherapy, Targeted Agents Transform Lung Cancer Paradigm, But Challenges Remain

March 17th 2020

Chad Cherington, MD, discusses groundbreaking developments and critical next steps across the spectrum in lung cancer.

More Research Required to Define Role of Cytoreductive Nephrectomy in RCC

March 13th 2020

Reza Mehrazin, MD, discusses the need for more research before determining the role of cytoreductive nephrectomy in an era of immunotherapy and targeted therapy.

TKI/Immunotherapy Combos Lead Advances in mRCC, But Questions Remain

March 11th 2020

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

Neoadjuvant Cisplatin Not Superior to Standard Chemo in BRCA+ HER2-Negative Breast Cancer

March 10th 2020

Single-agent cisplatin did not lead to significantly higher pathologic complete response rates or improved residual cancer burden scores compared with doxorubicin plus cyclophosphamide in the neoadjuvant setting for patients with stage I to III HER2-negative breast cancer who harbor BRCA mutations.

Sequencing Challenges, Novel Research Efforts Come to Forefront in HCC

March 9th 2020

Benjamin Leon Musher, MD, discusses sequencing challenges and research efforts needed regarding immunotherapy in hepatocellular carcinoma before it becomes a standard approach for patients.

GVHD Armamentarium Expanding, But Novel Treatments Still Needed

March 6th 2020

Madan Jagasia, MBBS, MS, MMHC, discusses the current treatment landscape and next steps in graft-versus-host-disease.

Upfront Multidrug Regimens Prove Beneficial in Myeloma

March 6th 2020

Marc J. Braunstein, MD, PhD, expands on the 3- and 4-drug regimens that are showing promise in the multiple myeloma paradigm.

John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma

March 4th 2020

An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab improves recurrence-free survival compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.

PROs Further Support Hypofractionated RT in Nonmetastatic Prostate Cancer

March 3rd 2020

The use of moderately hypofractionated radiation therapy demonstrated no statistically significant differences in functional outcomes compared with conventionally fractionated radiation therapy, further cementing hypofractionated radiation therapy as a standard approach for patients with nonmetastatic prostate cancer.

NEJM Data Highlight Neoadjuvant Pembrolizumab Benefit in TNBC

March 3rd 2020

The neoadjuvant combination of pembrolizumab plus chemotherapy led to a higher pathological complete response rate compared with placebo/chemotherapy in patients with early triple-negative breast cancer, across various patient subgroups.

Routine Cervical Cancer Screening Reduces Risk of Stage I/II+ Disease, But More Awareness Needed

March 3rd 2020

Routine cervical screening, conducted every 3 years, was found to reduce the incidence of stage I and stage II+ cervical cancers by 48% and 83%, respectively.